Kalsiyum Kanal Blokeri Kullanımının Periodontal Dokular Üzerine Patolojik Etkileri

Deniz Çetiner; Nazife Hamurcu; Abdulkadir Kemal Binici

Derleme

Kalsiyum Kanal Blokeri Kullanımının Periodontal Dokular Üzerine Patolojik Etkileri

Yıl 2021, Cilt: 10 Sayı: 1, 65 - 71, 28.01.2021

Deniz Çetiner , Nazife Hamurcu , Abdulkadir Kemal Binici

Öz

Mikrobiyal dental plağa dişetinin verdiği cevap konağın sistemik durumu ve kullandığı ilaçlar ile modifiye olabilmektedir. Multifaktöriyel enflamatuar periodontal hastalıkların kardiyovasküler hastalıklar ile karşılıklı ilişkisi kanıta dayalı çalışmalarla ortaya konmuştur. Kalsiyum kanal blokeri kullanımı hipertansiyon, anjina veya supraventriküler kardiyak aritmileri olan hastalarda tedavinin önemli bir bileşenidir. Dişeti büyümeleri, bu ilaçların ciddi bir yan etkisi olarak oral kavitede oldukça sık rastlanan bir olgu olarak karşımıza çıkmaktadır.

Anahtar Kelimeler

Dişeti büyümesi, Gingivektomi, Kalsiyum kanal blokerleri

Kaynakça

1. Grover V, Kapoor A, Marya C. Amlodipine induced gingival hyperplasia. J Oral Health Comm Dent 2007;1:19-22.
2. Trackman P, Kantarci A. Connective tissue metabolism and gingival overgrowth. Crit Rev Oral Biol Med 2004;15:165-75.
3. Triveni M, Rudrakshi C, Mehta D. Amlodipine-induced gingival overgrowth. J Indian Soc Periodontol 2009;13:160-3.
4. Dongari-Bagtzoglou A. Academy report. Informational paper. Drug-induced gingival enlargement. J Periodontol 2004;75:1424-31.
5. Silverstein LH, Koch JP, Lefkove MD, Garnick JJ, Singh B, Steflik DE. Nifedipine-induced gingival enlargement around dental implants: a clinical report. J Oral Implantol 1995;21:116-20.
6. Nayler WG, Dillon J. Calcium antagonists and their mode of action: an historical overview. Br J Clin Pharmacol 1986;21:97S-107S.
7. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy: report of a case. Oral Surg Oral Med Oral Pathol 1984;57:620-2.
8. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol 1999;70:63-7.
9. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontol 1994;65:260-7.
10. Ellis J, Seymour R, Thomason JM, Monkman S, Idle J. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet 1993;341:1102-3.
11. Miranda J, Brunet L, Roset P, Berini L, Farré M, Mendieta C. Prevalence and risk of gingival overgrowth in patients treated with diltiazem or verapamil. J Clin Periodontol 2005;32:294-8.
12. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992;63:453-6.
13. Andrew W, Evelyn W, Francis M, Mark J, Mark C. Pattern of gingival overgrowth among patients on antihypertensive pharmacotherapy at a Nairobi hospital in Kenya. Open Journal of Stomatology 2014;2014.
14. Nishikawa S, Nagata T, Morisaki I, Oka T, Ishida H. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. J Periodontol 1996;67:463-71.
15. Seymour R, Ellis J, Thomason J, Monkman S, Idle J. Amlodipine- induced gingival overgrowth. J Clin Periodontol 1994;21:281-3.
16. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J 1999;44:219-32.
17. Informational paper: drug-associated gingival enlargement. J Periodontol 2004;75:1424-31.
18. Ayanoglou C, Lesty C. Cyclosporin A-induced gingival overgrowth in the rat: a histological, ultrastructural and histomorphometric evaluation. J Periodontal Res 1999;34:7-15.
19. Castro LA, Elias LS, Oton-Leite AF, de Spíndula-Filho JV, Leles CR, Batista AC, et al. Long-term effects of nifedipine on human gingival epithelium: a histopathological and immunohistochemical study. J Oral Sci 2010;52:55-62.
20. Lindhe NPLJ. regenerative periodontal therapy 2008. 541-62 p.
21. Zuhr O, Bäumer D, Hürzeler M. The addition of soft tissue replacement grafts in plastic periodontal and implant surgery: critical elements in design and execution. J Clin Periodontol 2014;41:S123-42.
22. Nyska A, Shemesh M, Tal H, Dayan D. Gingival hyperplasia induced by calcium channel blockers: mode of action. Med Hypotheses 1994;43:115-8.
23. Lafzi A, Farahani RMZ, Shoja MAM. Amlodipine-induced gingival hyperplasia. Medicina Oral Patología Oral y Cirugía Bucal (Internet). 2006;11:480-2.
24. Bendtzen K. Cytokines and natural regulators of cytokines. Immunology letters. 1994;43:111-23.
25. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunology today. 2000;21:418-20.
26. Sume SS, Berker E, Ilarslan Y, Ozer Yucel O, Tan C, Goyushov S, et al. Elevated Interleukin-17A expression in amlodipine-induced gingival overgrowth. J Periodontal Res 2020;55:613-21.
27. Kose K, Yilmaz S, Noyan U, Kuru B, Yildirim H, Agrali O, et al. The gingival crevicular fluid levels of growth factors in patients with amlodipine-induced gingival overgrowth: A pilot study. Niger J Clin Pract 2020;23:561-7.
28.Seymour R, Ellis J, Thomason J. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27:217-23.
29. Caton JG, Armitage G, Berglundh T, Chapple IL, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions–Introduction and key changes from the 1999 classification. J Clin Periodontol 2018;89:S1-S8.
30. Armitage GC. Development of a classification system for periodontal diseases and conditions. Annals Periodontol 1999;4:1-6.
31. Seymour R, Thomason J, Ellis J. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-75.
32. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens 2014;28:10-4.
33. Ishida H, Kondoh T, Kataoka M, Nishikawa S, Nakagawa T, Morisaki I, et al. Factors influencing nifedipine-induced gingival overgrowth in rats. J Periodontol 1995;66:345-50.
34. Barclay S, Thomason J, Idle J, Seymour R. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992;19:311-4.
35. Jorgensen MG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontol 1997;68:676-8.
36. Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Azuma H, Sawa T, et al. Nifedipine induces gingival overgrowth in rats through a reduction in collagen phagocytosis by gingival fibroblasts. J Periodontol 2001;72:1078-83.
37. Dongari-Bagtzoglou A. Research, Science and therapy committee, american academy of periodontology. Drug-associated gingival enlargement. J Periodontol 2004;75:1424-31.
38. Seymour RA. Effects of medications on the periodontal tissues in health and disease. Periodontol 2000 2006;40:120-9.
39. Daley T, Wysocki G, Day C. Clinical and pharmacologic correlations in cyclosporine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986;62:417-21.
40. Lauritano D, Lucchese A, Di Stasio D, Della Vella F, Cura F, Palmieri A, et al. Molecular aspects of drug-induced gingival overgrowth: an in vitro study on amlodipine and gingival fibroblasts. Int J Mol Sci 2019;20:2047.
41. Hernández G, Arriba L, Lucas M, de Andrés A. Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus. J Periodontol 2000;71:1630-6.
42. Mavrogiannis M, Ellis J, Thomason J, Seymour R. The management of drug-induced gingival overgrowth. J Clin Periodontol 2006;33:434-9.
43. Camargo PM, Melnick PR, Pirih FQ, Lagos R, Takei HH. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2000 2001;27:131-8.
44. Camargo PM, Carranza FA, Takei H. Carranza’s clinical periodontology: WB Saunders Company 2006.
45. Mavrogiannis M, Ellis J, Seymour R, Thomason J. The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth. J Clin Periodontol 2006;33:677-82.
46. Pick RM, Colvard MD. Current status of lasers in soft tissue dental surgery. J Periodontol 1993;64:589-602.
47. Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. J Periodontol 1999;70:967-72.
48. Kantarci A, Cebeci I, Tuncer Ö, Çarin M, Firatli E. Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia. J Periodontol 1999;70:587-93.
49. Casamassimo PS. Relationships between oral and systemic health. Pediatr Clin North Am 2000;47:1149-57.
50. Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am Heart J 2007;154:830-7.

Pathological Effects of Calcium Channel Blockers on Periodontal Tissues

Yıl 2021, Cilt: 10 Sayı: 1, 65 - 71, 28.01.2021

Deniz Çetiner , Nazife Hamurcu , Abdulkadir Kemal Binici

Öz

The gingival response to the microbial dental plaque can be modified by the host’s systemic condition and the drugs used. The mutual relationship of multifactorial inflammatory periodontal diseases with cardiovascular diseases has been demonstrated by evidence-based studies. The use of calcium channel blockers is an important component of treatment in patients with hypertension, angina, or supraventricular cardiac arrhythmias. Gingival overgrowth is a very common occurrence in the oral cavity as a serious side effect of these drugs.

Anahtar Kelimeler

Calcium channel blockers, Gingival overgrowth, Gingivectomy

Kaynakça

1. Grover V, Kapoor A, Marya C. Amlodipine induced gingival hyperplasia. J Oral Health Comm Dent 2007;1:19-22.
2. Trackman P, Kantarci A. Connective tissue metabolism and gingival overgrowth. Crit Rev Oral Biol Med 2004;15:165-75.
3. Triveni M, Rudrakshi C, Mehta D. Amlodipine-induced gingival overgrowth. J Indian Soc Periodontol 2009;13:160-3.
4. Dongari-Bagtzoglou A. Academy report. Informational paper. Drug-induced gingival enlargement. J Periodontol 2004;75:1424-31.
5. Silverstein LH, Koch JP, Lefkove MD, Garnick JJ, Singh B, Steflik DE. Nifedipine-induced gingival enlargement around dental implants: a clinical report. J Oral Implantol 1995;21:116-20.
6. Nayler WG, Dillon J. Calcium antagonists and their mode of action: an historical overview. Br J Clin Pharmacol 1986;21:97S-107S.
7. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy: report of a case. Oral Surg Oral Med Oral Pathol 1984;57:620-2.
8. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol 1999;70:63-7.
9. Grossi SG, Zambon JJ, Ho AW, Koch G, Dunford RG, Machtei EE, et al. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. J Periodontol 1994;65:260-7.
10. Ellis J, Seymour R, Thomason JM, Monkman S, Idle J. Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet 1993;341:1102-3.
11. Miranda J, Brunet L, Roset P, Berini L, Farré M, Mendieta C. Prevalence and risk of gingival overgrowth in patients treated with diltiazem or verapamil. J Clin Periodontol 2005;32:294-8.
12. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992;63:453-6.
13. Andrew W, Evelyn W, Francis M, Mark J, Mark C. Pattern of gingival overgrowth among patients on antihypertensive pharmacotherapy at a Nairobi hospital in Kenya. Open Journal of Stomatology 2014;2014.
14. Nishikawa S, Nagata T, Morisaki I, Oka T, Ishida H. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. J Periodontol 1996;67:463-71.
15. Seymour R, Ellis J, Thomason J, Monkman S, Idle J. Amlodipine- induced gingival overgrowth. J Clin Periodontol 1994;21:281-3.
16. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J 1999;44:219-32.
17. Informational paper: drug-associated gingival enlargement. J Periodontol 2004;75:1424-31.
18. Ayanoglou C, Lesty C. Cyclosporin A-induced gingival overgrowth in the rat: a histological, ultrastructural and histomorphometric evaluation. J Periodontal Res 1999;34:7-15.
19. Castro LA, Elias LS, Oton-Leite AF, de Spíndula-Filho JV, Leles CR, Batista AC, et al. Long-term effects of nifedipine on human gingival epithelium: a histopathological and immunohistochemical study. J Oral Sci 2010;52:55-62.
20. Lindhe NPLJ. regenerative periodontal therapy 2008. 541-62 p.
21. Zuhr O, Bäumer D, Hürzeler M. The addition of soft tissue replacement grafts in plastic periodontal and implant surgery: critical elements in design and execution. J Clin Periodontol 2014;41:S123-42.
22. Nyska A, Shemesh M, Tal H, Dayan D. Gingival hyperplasia induced by calcium channel blockers: mode of action. Med Hypotheses 1994;43:115-8.
23. Lafzi A, Farahani RMZ, Shoja MAM. Amlodipine-induced gingival hyperplasia. Medicina Oral Patología Oral y Cirugía Bucal (Internet). 2006;11:480-2.
24. Bendtzen K. Cytokines and natural regulators of cytokines. Immunology letters. 1994;43:111-23.
25. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunology today. 2000;21:418-20.
26. Sume SS, Berker E, Ilarslan Y, Ozer Yucel O, Tan C, Goyushov S, et al. Elevated Interleukin-17A expression in amlodipine-induced gingival overgrowth. J Periodontal Res 2020;55:613-21.
27. Kose K, Yilmaz S, Noyan U, Kuru B, Yildirim H, Agrali O, et al. The gingival crevicular fluid levels of growth factors in patients with amlodipine-induced gingival overgrowth: A pilot study. Niger J Clin Pract 2020;23:561-7.
28.Seymour R, Ellis J, Thomason J. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27:217-23.
29. Caton JG, Armitage G, Berglundh T, Chapple IL, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions–Introduction and key changes from the 1999 classification. J Clin Periodontol 2018;89:S1-S8.
30. Armitage GC. Development of a classification system for periodontal diseases and conditions. Annals Periodontol 1999;4:1-6.
31. Seymour R, Thomason J, Ellis J. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996;23:165-75.
32. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens 2014;28:10-4.
33. Ishida H, Kondoh T, Kataoka M, Nishikawa S, Nakagawa T, Morisaki I, et al. Factors influencing nifedipine-induced gingival overgrowth in rats. J Periodontol 1995;66:345-50.
34. Barclay S, Thomason J, Idle J, Seymour R. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992;19:311-4.
35. Jorgensen MG. Prevalence of amlodipine-related gingival hyperplasia. J Periodontol 1997;68:676-8.
36. Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Azuma H, Sawa T, et al. Nifedipine induces gingival overgrowth in rats through a reduction in collagen phagocytosis by gingival fibroblasts. J Periodontol 2001;72:1078-83.
37. Dongari-Bagtzoglou A. Research, Science and therapy committee, american academy of periodontology. Drug-associated gingival enlargement. J Periodontol 2004;75:1424-31.
38. Seymour RA. Effects of medications on the periodontal tissues in health and disease. Periodontol 2000 2006;40:120-9.
39. Daley T, Wysocki G, Day C. Clinical and pharmacologic correlations in cyclosporine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1986;62:417-21.
40. Lauritano D, Lucchese A, Di Stasio D, Della Vella F, Cura F, Palmieri A, et al. Molecular aspects of drug-induced gingival overgrowth: an in vitro study on amlodipine and gingival fibroblasts. Int J Mol Sci 2019;20:2047.
41. Hernández G, Arriba L, Lucas M, de Andrés A. Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus. J Periodontol 2000;71:1630-6.
42. Mavrogiannis M, Ellis J, Thomason J, Seymour R. The management of drug-induced gingival overgrowth. J Clin Periodontol 2006;33:434-9.
43. Camargo PM, Melnick PR, Pirih FQ, Lagos R, Takei HH. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2000 2001;27:131-8.
44. Camargo PM, Carranza FA, Takei H. Carranza’s clinical periodontology: WB Saunders Company 2006.
45. Mavrogiannis M, Ellis J, Seymour R, Thomason J. The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth. J Clin Periodontol 2006;33:677-82.
46. Pick RM, Colvard MD. Current status of lasers in soft tissue dental surgery. J Periodontol 1993;64:589-602.
47. Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. J Periodontol 1999;70:967-72.
48. Kantarci A, Cebeci I, Tuncer Ö, Çarin M, Firatli E. Clinical effects of periodontal therapy on the severity of cyclosporin A-induced gingival hyperplasia. J Periodontol 1999;70:587-93.
49. Casamassimo PS. Relationships between oral and systemic health. Pediatr Clin North Am 2000;47:1149-57.
50. Bahekar AA, Singh S, Saha S, Molnar J, Arora R. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am Heart J 2007;154:830-7.

Toplam 50 adet kaynakça vardır.

Ayrıntılar

Birincil Dil	Türkçe
Konular	Diş Hekimliği
Bölüm	Derleme
Yazarlar	Deniz Çetiner 0000-0002-1903-2999 Nazife Hamurcu 0000-0002-6652-016X Abdulkadir Kemal Binici 0000-0002-7654-1036
Yayımlanma Tarihi	28 Ocak 2021
Gönderilme Tarihi	29 Aralık 2020
Yayımlandığı Sayı	Yıl 2021 Cilt: 10 Sayı: 1

Kaynak Göster

Vancouver	Çetiner D, Hamurcu N, Binici AK. Kalsiyum Kanal Blokeri Kullanımının Periodontal Dokular Üzerine Patolojik Etkileri. ADO Klinik Bilimler Dergisi. 2021;10(1):65-71.

Kapak Resmi İndir

Makale Dosyaları

Tam Metin